ATE502949T1 - Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen - Google Patents

Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen

Info

Publication number
ATE502949T1
ATE502949T1 AT04762006T AT04762006T ATE502949T1 AT E502949 T1 ATE502949 T1 AT E502949T1 AT 04762006 T AT04762006 T AT 04762006T AT 04762006 T AT04762006 T AT 04762006T AT E502949 T1 ATE502949 T1 AT E502949T1
Authority
AT
Austria
Prior art keywords
virus
odns
deoxidation
oligonucleotide
stranded
Prior art date
Application number
AT04762006T
Other languages
English (en)
Inventor
Yongli Yu
Liying Wang
Original Assignee
Changchun Huapu Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 03146157 external-priority patent/CN1289520C/zh
Priority claimed from CNB031562248A external-priority patent/CN1304412C/zh
Application filed by Changchun Huapu Biotechnology Co Ltd filed Critical Changchun Huapu Biotechnology Co Ltd
Application granted granted Critical
Publication of ATE502949T1 publication Critical patent/ATE502949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04762006T 2003-07-25 2004-07-26 Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen ATE502949T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN 03146157 CN1289520C (zh) 2003-07-25 2003-07-25 具有抗流感病毒的含CpG单链脱氧寡核苷酸
CNB031562248A CN1304412C (zh) 2003-09-05 2003-09-05 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸
PCT/CN2004/000863 WO2005014611A1 (en) 2003-07-25 2004-07-26 The artificial cpg single strand deoxidation oligonucleotide and its antiviral uses

Publications (1)

Publication Number Publication Date
ATE502949T1 true ATE502949T1 (de) 2011-04-15

Family

ID=34137222

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04762006T ATE502949T1 (de) 2003-07-25 2004-07-26 Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen
AT10174994T ATE532792T1 (de) 2003-07-25 2004-07-26 Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10174994T ATE532792T1 (de) 2003-07-25 2004-07-26 Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen

Country Status (8)

Country Link
US (1) US7491706B2 (de)
EP (2) EP1650218B1 (de)
JP (1) JP4809220B2 (de)
KR (1) KR101146203B1 (de)
AT (2) ATE502949T1 (de)
CA (1) CA2533434C (de)
DE (1) DE602004031946D1 (de)
WO (1) WO2005014611A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1829887B1 (de) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
CN1865275B (zh) 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2024245358A1 (zh) 2023-05-30 2024-12-05 四川三叶草生物制药有限公司 冠状病毒疫苗组合物、方法及其使用
CN121464149A (zh) 2023-06-07 2026-02-03 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1280303C (zh) * 2003-05-28 2006-10-18 长春华普生物技术有限公司 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用

Also Published As

Publication number Publication date
CA2533434C (en) 2011-07-05
JP2006528491A (ja) 2006-12-21
KR20060054354A (ko) 2006-05-22
KR101146203B1 (ko) 2012-05-25
EP1650218A4 (de) 2008-07-02
EP1650218A1 (de) 2006-04-26
JP4809220B2 (ja) 2011-11-09
CA2533434A1 (en) 2005-02-17
US20070155683A1 (en) 2007-07-05
ATE532792T1 (de) 2011-11-15
DE602004031946D1 (de) 2011-05-05
WO2005014611A1 (en) 2005-02-17
EP2264046A1 (de) 2010-12-22
EP2264046B1 (de) 2011-11-09
EP1650218B1 (de) 2011-03-23
US7491706B2 (en) 2009-02-17

Similar Documents

Publication Publication Date Title
FR21C1037I1 (fr) Clades de virus adéno associés (aav), séquences, vecteurs les contenant et leurs utilisations
WO2003070193A3 (en) RNA interference mediated inhibition of HIV gene expression using short interfering nucleic acid (siNA)
ATE442152T1 (de) Antisense-entwurf
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
EP1472267A4 (de) Durch rna-interferenz vermittelte inhibierung der genexpression von proteintyrosinphosphatase vom typ iva (prl3) unter verwendung kurzer interferierender nukleinsäure (sina)
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
ATE346918T1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
CY1108870T1 (el) Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους
WO2004039829A3 (en) Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
DE602004031946D1 (de) Das künstliche cpg single strand deoxidation-oligonukleotid und dessen antivirale anwendungen
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
WO2008068638A8 (en) Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
EP2270162A3 (de) Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
JP2006502694A5 (de)
DE69829760D1 (de) Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
WO1999009154A3 (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
WO2006121464A3 (en) Compositions for treating respiratory viral infections and their use
WO2006063281A3 (en) 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
BRPI9800337A (pt) par de iniciadores de oligonucleotídeos para a amplificação de ácido nucléico de tipo 1 (hiv-1) de vírus de imunodeficiência humana, conjunto de iniciadores, kits para detectar o dito ácido nucléico, bem como processo para referida amplificação.
JP2003219893A5 (de)
DE60110244D1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide
HRP20100666T1 (hr) ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE
DE60213406D1 (de) Pharmakologische anwendungen von mitochondriellen dna assays
WO2003031459A3 (de) Modulation der expression stat-1-abhängiger gene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties